Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.
Zificsak, Craig A; Gingrich, Diane E; Breslin, Henry J; Dunn, Derek D; Milkiewicz, Karen L; Theroff, Jay P; Thieu, Tho V; Underiner, Ted L; Weinberg, Linda R; Aimone, Lisa D; Albom, Mark S; Mason, Jennifer L; Saville, Lisa; Husten, Jean; Angeles, Thelma S; Finn, James P; Jan, Mahfuza; O'Kane, Teresa M; Dobrzanski, Pawel; Dorsey, Bruce D.
Bioorg Med Chem Lett
; 22(1): 133-7, 2012 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-22169263
4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
In silico identification of natural product inhibitors of JAK2.
Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening.
The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.
Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.
2-Alkylsulfanyl-4(5)-aryl-5(4)-heteroarylimidazoles: An Overview on Synthetic Strategies and Biological Activity.
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.